This is important, since it suggests that Elo binding to SLAMF7 on the surface of NK cells (as would occur in treated patients) can co-stimulate calcium signaling responses triggered by NKp46 and other ITAM-coupled receptors engaging with ligands on the surface of myeloma cells. Here, SLAMF7 is linked to plasma cell myeloma.